Familial Chylomicronemia Syndrome Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, Lipigon Pharmaceuticals, and others.

Posted on
by

Familial Chylomicronemia Syndrome Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, Lipigon Pharmaceuticals, and others.

(Albany, United States) As per DelveInsight’s assessment, globally, the Familial Chylomicronemia Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ Familial Chylomicronemia Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Familial Chylomicronemia Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Familial Chylomicronemia Syndrome NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Familial Chylomicronemia Syndrome Pipeline treatment landscape of the report, click here @ Familial Chylomicronemia Syndrome Pipeline Outlook

Key Takeaways from the Familial Chylomicronemia Syndrome Pipeline Report

  • DelveInsight’s Familial Chylomicronemia Syndrome Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
  • The leading companies are working in the Familial Chylomicronemia Syndrome market include Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, Lipigon Pharmaceuticals, and others.
  • Promising Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, LCQ908, sterile normal saline (0.9% NaCl), and others.
  • On June 2023, Arrowhead Pharmaceuticals announced a study of phase 3 clinical trials for ARO-APOC3. The purpose or AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of ARO-APOC3 or matching placebo administered subcutaneously.
  • On August 2023, Ionis Pharmaceuticals announced a study of phase 3 clinical trials for Olezarsen. The purpose of the study is to evaluate the efficacy of Olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Familial Chylomicronemia Syndrome Overview

Familial hyperchylomicronemia syndrome is a rare autosomal recessive metabolic disorder caused by the mutation in lipoprotein lipase. It correlates with significant morbidity and distress amongst the patients.

For further information, refer to the detailed Familial Chylomicronemia Unmet Needs, click here for Familial Chylomicronemia Ongoing Clinical Trial Analysis

Familial Chylomicronemia Syndrome Emerging Drugs

  • Olezarsen: Ionis Pharmaceuticals

Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.

Familial Chylomicronemia Syndrome Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Familial Chylomicronemia Syndrome. The Familial Chylomicronemia Syndrome companies which have their Familial Chylomicronemia Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

Request a sample and discover the recent advances in Familial Chylomicronemia Syndrome Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Familial Chylomicronemia Syndrome Segmentation

Familial Chylomicronemia Syndrome Drugs and Companies

  • ARO-APOC3: Arrowhead Pharmaceuticals
  • Olezarsen: Ionis Pharmaceuticals
  • Volanesorsen: Akcea Therapeutics

Familial Chylomicronemia Syndrome Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Some of the Companies in the Familial Chylomicronemia Syndrome Therapeutics Market include-

Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, Lipigon Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Familial Chylomicronemia Syndrome Pipeline, click here for Familial Chylomicronemia Syndrome Unmet Needs and Analyst Views

Scope of the Familial Chylomicronemia Syndrome Pipeline Report

  • Coverage- Global
  • Companies- Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, Lipigon Pharmaceuticals, and others.
  • Therapies- Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, LCQ908, sterile normal saline (0.9% NaCl), and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Familial Chylomicronemia Syndrome Merger and acquisitions, Licensing Activities

Table of Content

  1. Introduction
  2. Executive Summary
  3. Familial Chylomicronemia Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Familial Chylomicronemia Syndrome – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Olezarsen: Ionis Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Lipisense: Lipigon Pharmaceuticals
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Familial Chylomicronemia Syndrome Key Companies
  24. Familial Chylomicronemia Syndrome Key Products
  25. Familial Chylomicronemia Syndrome – Unmet Needs
  26. Familial Chylomicronemia Syndrome – Market Drivers and Barriers
  27. Familial Chylomicronemia Syndrome – Future Perspectives and Conclusion
  28. Familial Chylomicronemia Syndrome Analyst Views
  29. Familial Chylomicronemia Syndrome Key Companies
  30. Appendix

 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services